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Sir,
We read the recently published article by Soo et al (2005) with
great interest. They compared adjuvant radiotherapy following
surgery with combined radiochemotherapy for locally advanced
head and neck cancer. They could find no significant difference in
the 3-year disease-free survival rate between the two methods of
treatment. As we felt that some important points were missing in
their paper, we would like to discuss these issues in the following.
We give the authors great credit for releasing the data of a trial
that was prematurely stopped due to the slow accrual rate before
the intended recruitment of 200 patients was reached. Considering
the small size of the sample and the frequent deviation from
protocol, it is questionable whether the trial is in a position to
detect a significant difference at all. Contrary to the presented
conclusion, the reported data such as the 3-year disease-free
survival rate, 50 vs 40%, create the strong impression of an inferior
outcome as a result of their combined radiochemotherapy.
Although this difference did not reach statistical significance, it
becomes more critical when compared to established radio-
chemotherapy regimens. For example, in the case of a daily
fractionated radiation, the total dose should not be less than 70Gy
(Adelstein et al, 2003). Therefore, the total dose of 66Gy, which
was used in the study must be viewed as insufficient. Even in the
case of hyperfractionated accelerated radiochemotherapy in locally
advanced head and neck cancer, the applied total dose should not
fall below 70Gy, as recently published (Budach et al, 2005).
The authors report a much higher rate of grade 3 toxicity of the
radiochemotherapy in comparison to their adjuvant radiotherapy
method. Normally, higher toxicity is connected with treatment
interruptions and, ultimately, with longer overall treatment time.
Furthermore, it is known that longer overall treatment time can
cause a reduction in the survival rate as well as in local control
(Dietl et al, 2005). Moreover, higher toxicity can decrease the
patient’s quality of life in general. The above-mentioned inferiority
of the combined treatment modality could thus be caused by the
higher rate of grade 3 toxicity.
The authors rightly describe the low accrual rate as the major
problem of their study. Unfortunately, they did not identify the
cause for the low accrural rate which, we presume, is rooted in the
study design. They selected patients with resectable head and neck
cancer for their trial, but it is highly probable that such patients
prefer surgery. Therefore, most studies concerning radioche-
motherapy of head and neck cancer deal with unresectable
tumours (Soo et al, 2005). The authors thus owe their readers an
explanation as to which criteria they applied in distinguishing
resectable from unresectable tumours. They point out the higher
rate of organ-perservation in the laryngeal/hypopharyngeal disease
vs the rest (68 vs 30%). This could be understood to mean that the
authors had second thoughts as to whether every resectable
tumour is preferably treated by surgery rather than radio-
chemotherapy. Therefore, we would like to pose the question as
to which T4 tumours (56% of all patients) should be operated,
especially under consideration of quality of life and loss of organ
function. Resectable laryngeal cancer can set an impressive
example as a recent prospective study was able to show (Forastiere
et al, 2003). It was found that radiotherapy with concurrent
cisplatin should be considered standard care for patients desiring
laryngeal preservation whose cancer was within the categories of
disease studied in their trial, and a laryngectomy should be
performed only as a salvage therapy. It was concluded that, in most
patients with laryngeal cancer, the disease can be managed without
a primary surgical approach.
To make a long story short, we see two negative consequences of
the applied study design, and the randomisation of resectable
tumours. One consequence is the low accrual rate and the other is
performance of surgery on patients who do not require such an
intervention, as in the case of laryngeal cancer. The authors could
not recognise this fact since they did not analyse quality of life
among their patients. The abandonment of surgery can often be
justified by quality of life considerations, as in the case of organ
preservation. Regrettably, quality of life parameters were not
included in this study.
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